Cancer-associated thrombosis

Critical Reviews in Oncology/Hematology

Volumn 62, Issue 2, 2007, Pages 126-136

  Zwicker, Jeffrey I ^a   Furie, Barbara C ^a   Furie, Bruce ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Cancer thrombosis; Malignancy; Venous thromboembolic events (VTE)

Indexed keywords

BLOOD CLOTTING FACTOR 8; GAMMA INTERFERON; THROMBOPLASTIN; TUMOR NECROSIS FACTOR;

BLOOD CLOTTING; CARCINOGENESIS; CATHETER; ENDOTHELIUM CELL; HUMAN; INFLAMMATION; MOLECULAR DYNAMICS; NONHUMAN; REVIEW; THROMBOPHILIA; TUMOR CELL; VENOUS THROMBOEMBOLISM;

ANIMALS; BIOLOGICAL MARKERS; BLOOD COAGULATION; HUMANS; NEOPLASMS; THROMBOSIS;

EID: 34147125963     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2007.01.001     Document Type: Review

References (152)

1. Khorana A.A. Malignancy, thrombosis and Trousseau: the case for an eponym. J Thromb Haemost 1 (2003) 2463-2465
2. Monreal M., Lensing A.W., Prins M.H., et al. Screening for occult cancer in patients with acute deep vein thrombosis or pulmonary embolism. J Thromb Haemost 2 (2004) 876-881
3. Prandoni P., Lensing A.W., Buller H.R., et al. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med 327 (1992) 1128-1133
4. Bastounis E.A., Karayiannakis A.J., Makri G.G., Alexiou D., and Papalambros E.L. The incidence of occult cancer in patients with deep venous thrombosis: a prospective study. J Intern Med 239 (1996) 153-156
5. Hettiarachchi R.J., Lok J., Prins M.H., Buller H.R., and Prandoni P. Undiagnosed malignancy in patients with deep vein thrombosis: incidence, risk indicators, and diagnosis. Cancer 83 (1998) 180-185
6. Heit J.A., O'Fallon W.M., Petterson T.M., et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med 162 (2002) 1245-1248
7. Svendsen E., and Karwinski B. Prevalence of pulmonary embolism at necropsy in patients with cancer. J Clin Pathol 42 (1989) 805-809
8. Ambrus J.L., Ambrus C.M., Mink I.B., and Pickren J.W. Causes of death in cancer patients. J Med 6 (1975) 61-64
9. Mao C., Domenico D.R., Kim K., Hanson D.J., and Howard J.M. Observations on the developmental patterns and the consequences of pancreatic exocrine adenocarcinoma. Findings of 154 autopsies. Arch Surg 130 (1995) 125-134
10. Heit J.A., Silverstein M.D., Mohr D.N., Petterson T.M., O'Fallon W.M., and Melton III L.J. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 160 (2000) 809-815
11. Cuzick J., Forbes J., Edwards R., et al. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 360 (2002) 817-824
12. Fisher B., Costantino J.P., Wickerham D.L., et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90 (1998) 1371-1388
13. Cuzick J., Powles T., Veronesi U., et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet 361 (2003) 296-300
14. Pritchard K.I., Paterson A.H., Paul N.A., Zee B., Fine S., and Pater J. Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group. J Clin Oncol 14 (1996) 2731-2737
15. Heymach J.V., Desai J., Manola J., et al. Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas. Clin Cancer Res 10 (2004) 5732-5740
16. Kabbinavar F., Hurwitz H.I., Fehrenbacher L., et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21 (2003) 60-65
17. Cavo M., Zamagni E., Cellini C., et al. Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy. Blood 100 (2002) 2272-2273
18. Zangari M., Barlogie B., Anaissie E., et al. Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. Br J Haematol 126 (2004) 715-721
19. Zangari M., Anaissie E., Barlogie B., et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 98 (2001) 1614-1615
20. Di Carlo V., Agnelli G., Prandoni P., et al. Dermatan sulphate for the prevention of postoperative venous thromboembolism in patients with cancer. DOS (Dermatan sulphate in Oncologic Surgery) Study Group. Thromb Haemost 82 (1999) 30-34
21. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment. ENOXACAN Study Group. Br J Surg 1997;84:1099-103.
22. Levitan N., Dowlati A., Remick S.C., et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore) 78 (1999) 285-291
23. Blom J.W., Vanderschoot J.P., Oostindier M.J., Osanto S., van der Meer F.J., and Rosendaal F.R. Incidence of venous thrombosis in a large cohort of 66, 329 cancer patients: results of a record linkage study. J Thromb Haemost 4 (2006) 529-535
24. Haas S., Kakkar A.K., Kemkes-Matthes B., et al. Prevention of venous thromboembolism with low molecular weight heparin in patients with metastatic breast or lung cancer-Results of the TOPIC studies (2005), ISTH, Sydney, Australia
25. Miller G.J., Bauer K.A., Howarth D.J., Cooper J.A., Humphries S.E., and Rosenberg R.D. Increased incidence of neoplasia of the digestive tract in men with persistent activation of the coagulant pathway. J Thromb Haemost 2 (2004) 2107-2114
26. Edwards R.L., Rickles F.R., Moritz T.E., et al. Abnormalities of blood coagulation tests in patients with cancer. Am J Clin Pathol 88 (1987) 596-602
27. Buccheri G., Ferrigno D., Ginardi C., and Zuliani C. Haemostatic abnormalities in lung cancer: prognostic implications. Eur J Cancer 33 (1997) 50-55
28. Johnson M.J., Walker I.D., Sproule M.W., and Conkie J. Abnormal coagulation and deep venous thrombosis in patients with advanced cancer. Clin Lab Haematol 21 (1999) 51-54
29. Goldenberg N., Kahn S.R., and Solymoss S. Markers of coagulation and angiogenesis in cancer-associated venous thromboembolism. J Clin Oncol 21 (2003) 4194-4199
30. Sallah S., Wan J.Y., Nguyen N.P., Hanrahan L.R., and Sigounas G. Disseminated intravascular coagulation in solid tumors: clinical and pathologic study. Thromb Haemost 86 (2001) 828-833
31. Sallah S., Husain A., Sigounas V., et al. Plasma coagulation markers in patients with solid tumors and venous thromboembolic disease receiving oral anticoagulation therapy. Clin Cancer Res 10 (2004) 7238-7243
32. Kohli M., Fink L.M., Spencer H.J., and Zent C.S. Advanced prostate cancer activates coagulation: a controlled study of activation markers of coagulation in ambulatory patients with localized and advanced prostate cancer. Blood Coagul Fibrinolysis 13 (2002) 1-5
33. Nand S., Fisher S.G., Salgia R., and Fisher R.I. Hemostatic abnormalities in untreated cancer: incidence and correlation with thrombotic and hemorrhagic complications. J Clin Oncol 5 (1987) 1998-2003
34. Sun N.C., McAfee W.M., Hum G.J., and Weiner J.M. Hemostatic abnormalities in malignancy, a prospective study of one hundred eight patients. Part I. Coagulation studies. Am J Clin Pathol 71 (1979) 10-16
35. Falanga A., Ofosu F.A., Cortelazzo S., et al. Preliminary study to identify cancer patients at high risk of venous thrombosis following major surgery. Br J Haematol 85 (1993) 745-750
36. Iversen L.H., Okholm M., and Thorlacius-Ussing O. Pre- and postoperative state of coagulation and fibrinolysis in plasma of patients with benign and malignant colorectal disease-a preliminary study. Thromb Haemost 76 (1996) 523-528
37. Tas F., Duranyildiz D., Argon A., et al. Serum levels of leptin and proinflammatory cytokines in advanced-stage non-small cell lung cancer. Med Oncol 22 (2005) 353-358
38. De Vita F., Orditura M., Auriemma A., Infusino S., and Catalano G. Serum concentrations of proinflammatory cytokines in advanced non small cell lung cancer patients. J Exp Clin Cancer Res 17 (1998) 413-417
39. Gunter M.J., Stolzenberg-Solomon R., Cross A.J., et al. A prospective study of serum C-reactive protein and colorectal cancer risk in men. Cancer Res 66 (2006) 2483-2487
40. Schwager I., and Jungi T.W. Effect of human recombinant cytokines on the induction of macrophage procoagulant activity. Blood 83 (1994) 152-160
41. Del Prete G., De Carli M., Lammel R.M., et al. Th1 and Th2 T-helper cells exert opposite regulatory effects on procoagulant activity and tissue factor production by human monocytes. Blood 86 (1995) 250-257
42. Conkling P.R., Greenberg C.S., and Weinberg J.B. Tumor necrosis factor induces tissue factor-like activity in human leukemia cell line U937 and peripheral blood monocytes. Blood 72 (1988) 128-133
43. Zucchella M., Pacchiarini L., Meloni F., et al. Effect of interferon alpha, interferon gamma and tumor necrosis factor on the procoagulant activity of human cancer cells. Haematologica 78 (1993) 282-286
44. Tanaka M. Induction of tissue factor-like activity of human monoblastic leukemia cell line by tumor necrosis factor-alpha. Thromb Res 56 (1989) 201-211
45. Conkling P.R., Chua C.C., Nadler P., et al. Clinical trials with human tumor necrosis factor: in vivo and in vitro effects on human mononuclear phagocyte function. Cancer Res 48 (1988) 5604-5609
46. Muggia F.M., Brown T.D., Goodman P.J., et al. High incidence of coagualopathy in phase II studies of recombinant tumor necrosis factor in advanced pancreatic and gastric cancers. Anticancer Drugs 3 (1992) 211-217
47. Szotowski B., Antoniak S., Poller W., Schultheiss H.P., and Rauch U. Procoagulant soluble tissue factor is released from endothelial cells in response to inflammatory cytokines. Circ Res 96 (2005) 1233-1239
48. Cermak J., Key N.S., Bach R.R., Balla J., Jacob H.S., and Vercellotti G.M. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood 82 (1993) 513-520
49. Conway E.M., and Rosenberg R.D. Tumor necrosis factor suppresses transcription of the thrombomodulin gene in endothelial cells. Mol Cell Biol 8 (1988) 5588-5592
50. Faust S.N., Levin M., Harrison O.B., et al. Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N Engl J Med 345 (2001) 408-416
51. Fox E.A., and Kahn S.R. The relationship between inflammation and venous thrombosis. A systematic review of clinical studies. Thromb Haemost 94 (2005) 362-365
52. Kyrle P.A., Minar E., Hirschl M., et al. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med 343 (2000) 457-462
53. Kamphuisen P.W., Eikenboom J.C., Rosendaal F.R., et al. High factor VIII antigen levels increase the risk of venous thrombosis but are not associated with polymorphisms in the von Willebrand factor and factor VIII gene. Br J Haematol 115 (2001) 156-158
54. Koster T., Blann A.D., Briet E., Vandenbroucke J.P., and Rosendaal F.R. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 345 (1995) 152-155
55. O'Donnell J., Mumford A.D., Manning R.A., and Laffan M. Elevation of FVIII: C in venous thromboembolism is persistent and independent of the acute phase response. Thromb Haemost 83 (2000) 10-13
56. Kamphuisen P.W., Eikenboom J.C., Vos H.L., et al. Increased levels of factor VIII and fibrinogen in patients with venous thrombosis are not caused by acute phase reactions. Thromb Haemost 81 (1999) 680-683
57. Tesselaar M.E., Ouwerkerk J., Nooy M.A., Rosendaal F.R., and Osanto S. Risk factors for catheter-related thrombosis in cancer patients. Eur J Cancer 40 (2004) 2253-2259
58. Minnema M.C., Fijnheer R., De Groot P.G., and Lokhorst H.M. Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment. J Thromb Haemost 1 (2003) 445-449
59. Tsai A.W., Cushman M., Rosamond W.D., et al. Coagulation factors, inflammation markers, and venous thromboembolism: the longitudinal investigation of thromboembolism etiology (LITE). Am J Med 113 (2002) 636-642
60. Blann A.D., Gurney D., Wadley M., Bareford D., Stonelake P., and Lip G.Y. Increased soluble P-selectin in patients with haematological and breast cancer: a comparison with fibrinogen, plasminogen activator inhibitor and von Willebrand factor. Blood Coagul Fibrinolysis 12 (2001) 43-50
61. Mannucci P.M., Karimi M., Mosalaei A., Canciani M.T., and Peyvandi F. Patients with localized and disseminated tumors have reduced but measurable levels of ADAMTS-13 (von Willebrand factor cleaving protease). Haematologica 88 (2003) 454-458
62. Koo B.H., Oh D., Chung S.Y., et al. Deficiency of von Willebrand factor-cleaving protease activity in the plasma of malignant patients. Thromb Res 105 (2002) 471-476
63. Gordon S.G., Franks J.J., and Lewis B. Cancer procoagulant A: a factor X activating procoagulant from malignant tissue. Thromb Res 6 (1975) 127-137
64. Gordon S.G. A proteolytic procoagulant associated with malignant transformation. J Histochem Cytochem 29 (1981) 457-463
65. Kozwich D.L., Kramer L.C., Mielicki W.P., Fotopoulos S.S., and Gordon S.G. Application of cancer procoagulant as an early detection tumor marker. Cancer 74 (1994) 1367-1376
66. Mielicki W.P., Tenderenda M., Rutkowski P., and Chojnowski K. Activation of blood coagulation and the activity of cancer procoagulant (EC 3.4. 22. 26) in breast cancer patients. Cancer Lett 146 (1999) 61-66
67. Francis J.L., el-Baruni K., Roath O.S., and Taylor I. Factor X-activating activity in normal and malignant colorectal tissue. Thromb Res 52 (1988) 207-217
68. Raasi S., Mielicki W.P., Gordon S.G., and Korte W. Properties of proteins in cancer procoagulant preparations that are detected by anti-tissue factor antibodies. Arch Biochem Biophys 428 (2004) 131-135
69. Komiyama Y., Pedersen A.H., and Kisiel W. Proteolytic activation of human factors IX and X by recombinant human factor VIIa: effects of calcium, phospholipids, and tissue factor. Biochemistry 29 (1990) 9418-9425
70. Eiseman G., and Stefanini M. Thromboplastic activity of leukemic white cells. Proc Soc Exp Biol Med 86 (1954) 763-765
71. Gralnick H.R., and Abrell E. Studies of the procoagulant and fibrinolytic activity of promyelocytes in acute promyelocytic leukaemia. Br J Haematol 24 (1973) 89-99
72. Gouault Heilmann M., Chardon E., Sultan C., and Josso F. The procoagulant factor of leukaemic promyelocytes: demonstration of immunologic cross reactivity with human brain tissue factor. Br J Haematol 30 (1975) 151-158
73. Wada H., Nagano T., Tomeoku M., et al. Coagulant and fibrinolytic activities in the leukemic cell lysates. Thromb Res 30 (1983) 315-322
74. Shoji M., Hancock W.W., Abe K., et al. Activation of coagulation and angiogenesis in cancer: immunohistochemical localization in situ of clotting proteins and vascular endothelial growth factor in human cancer. Am J Pathol 152 (1998) 399-411
75. Rao L.V. Tissue factor as a tumor procoagulant. Cancer Metastasis Rev 11 (1992) 249-266
76. Edwards R.L., Rickles F.R., and Cronlund M. Abnormalities of blood coagulation in patients with cancer. Mononuclear cell tissue factor generation. J Lab Clin Med 98 (1981) 917-928
77. Cozzolino F., Torcia M., Miliani A., et al. Potential role of interleukin-1 as the trigger for diffuse intravascular coagulation in acute nonlymphoblastic leukemia. Am J Med 84 (1988) 240-250
78. Mechtcheriakova D., Wlachos A., Holzmuller H., Binder B.R., and Hofer E. Vascular endothelial cell growth factor-induced tissue factor expression in endothelial cells is mediated by EGR-1. Blood 93 (1999) 3811-3823
79. Zhang Y., Deng Y., Luther T., et al. Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J Clin Invest 94 (1994) 1320-1327
80. Rong Y., Post D.E., Pieper R.O., Durden D.L., Van Meir E.G., and Brat D.J. PTEN and hypoxia regulate tissue factor expression and plasma coagulation by glioblastoma. Cancer Res 65 (2005) 1406-1413
81. Yu J.L., May L., Lhotak V., et al. Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis 10.1182/blood-2004-05-2042. Blood 105 (2005) 1734-1741
82. Rauch U., Antoniak S., Boots M., et al. Association of tissue-factor upregulation in squamous-cell carcinoma of the lung with increased tissue factor in circulating blood. Lancet Oncol 6 (2005) 254
83. Forster Y., Meye A., Albrecht S., et al. Tissue specific expression and serum levels of human tissue factor in patients with urological cancer. Cancer Lett 193 (2003) 65-73
84. Giesen P.L., Rauch U., Bohrmann B., et al. Blood-borne tissue factor: another view of thrombosis. Proc Natl Acad Sci USA 96 (1999) 2311-2315
85. Falati S., Liu Q., Gross P., et al. Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin. J Exp Med 197 (2003) 1585-1598
86. Chou J., Mackman N., Merrill-Skoloff G., Pedersen B., Furie B.C., and Furie B. Hematopoietic cell-derived microparticle tissue factor contributes to fibrin formation during thrombus propagation. Blood 104 (2004) 3190-3197
87. Wolf P. The nature and significance of platelet products in human plasma. Br J Haematol 13 (1967) 269-288
88. Sims P.J., Faioni E.M., Wiedmer T., and Shattil S.J. Complement proteins C5b-9 cause release of membrane vesicles from the platelet surface that are enriched in the membrane receptor for coagulation factor Va and express prothrombinase activity. J Biol Chem 263 (1988) 18205-18212
89. Gilbert G.E., Sims P.J., Wiedmer T., Furie B., Furie B.C., and Shattil S.J. Platelet-derived microparticles express high affinity receptors for factor VIII. J Biol Chem 266 (1991) 17261-17268
90. Hoffman M., Monroe D.M., and Roberts H.R. Coagulation factor IXa binding to activated platelets and platelet-derived microparticles: a flow cytometric study. Thromb Haemost 68 (1992) 74-78
91. Sims P.J., Wiedmer T., Esmon C.T., Weiss H.J., and Shattil S.J. Assembly of the platelet prothrombinase complex is linked to vesiculation of the platelet plasma membrane. Studies in Scott syndrome: an isolated defect in platelet procoagulant activity. J Biol Chem 264 (1989) 17049-17057
92. Knijff-Dutmer E.A., Koerts J., Nieuwland R., Kalsbeek-Batenburg E.M., and van de Laar M.A. Elevated levels of platelet microparticles are associated with disease activity in rheumatoid arthritis. Arthritis Rheum 46 (2002) 1498-1503
93. Biro E., Sturk-Maquelin K.N., Vogel G.M., et al. Human cell-derived microparticles promote thrombus formation in vivo in a tissue factor-dependent manner. J Thromb Haemost 1 (2003) 2561-2568
94. Aras O., Shet A., Bach R.R., et al. Induction of microparticle- and cell-associated intravascular tissue factor in human endotoxemia. Blood 103 (2004) 4545-4553
95. Nieuwland R., Berckmans R.J., McGregor S., et al. Cellular origin and procoagulant properties of microparticles in meningococcal sepsis. Blood 95 (2000) 930-935
96. Nieuwland R., Berckmans R.J., Rotteveel-Eijkman R.C., et al. Cell-derived microparticles generated in patients during cardiopulmonary bypass are highly procoagulant. Circulation 96 (1997) 3534-3541
97. Jimenez J.J., Jy W., Mauro L.M., Horstman L.L., and Ahn Y.S. Elevated endothelial microparticles in thrombotic thrombocytopenic purpura: findings from brain and renal microvascular cell culture and patients with active disease. Br J Haematol 112 (2001) 81-90
98. Shet A.S., Aras O., Gupta K., et al. Sickle blood contains tissue factor-positive microparticles derived from endothelial cells and monocytes. Blood 102 (2003) 2678-2683
99. Berckmans R.J., Neiuwland R., Boing A.N., Romijn F.P., Hack C.E., and Sturk A. Cell-derived microparticles circulate in healthy humans and support low grade thrombin generation. Thromb Haemost 85 (2001) 639-646
100. Ando M., Iwata A., Ozeki Y., Tsuchiya K., Akiba T., and Nihei H. Circulating platelet-derived microparticles with procoagulant activity may be a potential cause of thrombosis in uremic patients. Kidney Int 62 (2002) 1757-1763
101. Mallat Z., Benamer H., Hugel B., et al. Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes. Circulation 101 (2000) 841-843
102. Dvorak H.F., Quay S.C., Orenstein N.S., et al. Tumor shedding and coagulation. Science 212 (1981) 923-924
103. Guha A., Bach R., Konigsberg W., and Nemerson Y. Affinity purification of human tissue factor: interaction of factor VII and tissue factor in detergent micelles. Proc Natl Acad Sci USA 83 (1986) 299-302
104. Dvorak H.F., Van DeWater L., Bitzer A.M., et al. Procoagulant activity associated with plasma membrane vesicles shed by cultured tumor cells. Cancer Res 43 (1983) 4434-4442
105. Bastida E., Ordinas A., Escolar G., and Jamieson G.A. Tissue factor in microvesicles shed from U87MG human glioblastoma cells induces coagulation, platelet aggregation, and thrombogenesis. Blood 64 (1984) 177-184
106. Carr J.M., Dvorak A.M., and Dvorak H.F. Circulating membrane vesicles in leukemic blood. Cancer Res 45 (1985) 5944-5951
107. Bona R., Lee E., and Rickles F. Tissue factor apoprotein: intracellular transport and expression in shed membrane vesicles. Thromb Res 48 (1987) 487-500
108. Yu J.L., and Rak J.W. Shedding of tissue factor (TF)-containing microparticles rather than alternatively spliced TF is the main source of TF activity released from human cancer cells. J Thromb Haemost 2 (2004) 2065-2067
109. Shapiro H.M. Practical Flow Cytometry. 3rd ed. (1995), Wiley-Liss, New York
110. Hercher M., Mueller W., and Shapiro H.M. Detection and discrimination of individual viruses by flow cytometry. J Histochem Cytochem 27 (1979) 350-352
111. Steen H.B. Flow cytometer for measurement of the light scattering of viral and other submicroscopic particles. Cytometry A 57 (2004) 94-99
112. Steen H.B. Light scattering measurement in an arc lamp-based flow cytometer. Cytometry 11 (1990) 223-230
113. Zwicker J.I., Furie B., Kos C., LaRocca T., Bauer K.A., and Furie B.C. Trousseau's syndrome revisited: tissue factor-bearing microparticles in pancreatic cancer. Blood 106 (2005) [abstract #259]
114. Rak J., Milsom C., May L., Klement P., and Yu J. Tissue factor in cancer and angiogenesis: the molecular link between genetic tumor progression, tumor neovascularization, and cancer coagulopathy. Semin Thromb Hemost 32 (2006) 54-70
115. Hjortoe G.M., Petersen L.C., Albrektsen T., et al. Tissue factor-factor VIIa-specific up-regulation of IL-8 expression in MDA-MB-231 cells is mediated by PAR-2 and results in increased cell migration. Blood 103 (2004) 3029-3037
116. Contrino J., Hair G., Kreutzer D.L., and Rickles F.R. In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease. Nat Med 2 (1996) 209-215
117. Carmeliet P., Mackman N., Moons L., et al. Role of tissue factor in embryonic blood vessel development. Nature 383 (1996) 73-75
118. Abe K., Shoji M., Chen J., et al. Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor. Proc Natl Acad Sci USA 96 (1999) 8663-8668
119. Griffin C.T., Srinivasan Y., Zheng Y.W., Huang W., and Coughlin S.R. A role for thrombin receptor signaling in endothelial cells during embryonic development. Science 293 (2001) 1666-1670
120. Ma L., Perini R., McKnight W., et al. Proteinase-activated receptors 1 and 4 counter-regulate endostatin and VEGF release from human platelets. Proc Natl Acad Sci USA 102 (2005) 216-220
121. Belting M., Dorrell M.I., Sandgren S., et al. Regulation of angiogenesis by tissue factor cytoplasmic domain signaling. Nat Med 10 (2004) 502-509
122. Bogdanov V.Y., Balasubramanian V., Hathcock J., Vele O., Lieb M., and Nemerson Y. Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein. Nat Med 9 (2003) 458-462
123. Boccaccio C., Sabatino G., Medico E., et al. The MET oncogene drives a genetic programme linking cancer to haemostasis. Nature 434 (2005) 396-400
124. Sciacca F.L., Ciusani E., Silvani A., et al. Genetic and plasma markers of venous thromboembolism in patients with high grade glioma 10.1158/1078-0432. CCR-03-0198. Clin Cancer Res 10 (2004) 1312-1317
125. Erickson L.A., Fici G.J., Lund J.E., Boyle T.P., Polites H.G., and Marotti K.R. Development of venous occlusions in mice transgenic for the plasminogen activator inhibitor-1 gene. Nature 346 (1990) 74-76
126. Farrehi P.M., Ozaki C.K., Carmeliet P., and Fay W.P. Regulation of arterial thrombolysis by plasminogen activator inhibitor-1 in mice. Circulation 97 (1998) 1002-1008
127. Kawasaki T., Dewerchin M., Lijnen H.R., Vermylen J., and Hoylaerts M.F. Vascular release of plasminogen activator inhibitor-1 impairs fibrinolysis during acute arterial thrombosis in mice. Blood 96 (2000) 153-160
128. Andren-Sandberg A., Lecander I., Martinsson G., and Astedt B. Peaks in plasma plasminogen activator inhibitor-1 concentration may explain thrombotic events in cases of pancreatic carcinoma. Cancer 69 (1992) 2884-2887
129. Durand M.K., Bodker J.S., Christensen A., et al. Plasminogen activator inhibitor-I and tumour growth, invasion, and metastasis. Thromb Haemost 91 (2004) 438-449
130. Mitchell L.G., Andrew M., Hanna K., et al. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase: results of the Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase (PARKAA) Study. Cancer 97 (2003) 508-516
131. De Cicco M., Matovic M., Balestreri L., et al. Central venous thrombosis: an early and frequent complication in cancer patients bearing long-term silastic catheter. A prospective study. Thromb Res 86 (1997) 101-113
132. Male C., Chait P., Andrew M., Hanna K., Julian J., and Mitchell L. Central venous line-related thrombosis in children: association with central venous line location and insertion technique. Blood 101 (2003) 4273-4278
133. Verso M., Agnelli G., Bertoglio S., et al. Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind, placebo-controlled, randomized study in cancer patients. J Clin Oncol 23 (2005) 4057-4062
134. Couban S., Goodyear M., Burnell M., et al. Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer. J Clin Oncol 23 (2005) 4063-4069
135. Mandala M., Curigliano G., Bucciarelli P., et al. Factor V Leiden and G20210A prothrombin mutation and the risk of subclavian vein thrombosis in patients with breast cancer and a central venous catheter. Ann Oncol 15 (2004) 590-593
136. Van Rooden C.J., Rosendaal F.R., Meinders A.E., Van Oostayen J.A., Van Der Meer F.J., and Huisman M.V. The contribution of factor V Leiden and prothrombin G20210A mutation to the risk of central venous catheter-related thrombosis. Haematologica 89 (2004) 201-206
137. Otten H.M., Mathijssen J., ten Cate H., et al. Symptomatic venous thromboembolism in cancer patients treated with chemotherapy: an underestimated phenomenon. Arch Intern Med 164 (2004) 190-194
138. Khorana A.A., Francis C.W., Culakova E., and Lyman G.H. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer 104 (2005) 2822-2829
139. Barbui T., Finazzi G., Grassi A., and Marchioli R. Thrombosis in cancer patients treated with hematopoietic growth factors-a meta-analysis. On behalf of the Subcommittee on Haemostasis and Malignancy of the Scientific and Standardization Committee of the ISTH. Thromb Haemost 75 (1996) 368-371
140. Rogers II J.S., Murgo A.J., Fontana J.A., and Raich P.C. Chemotherapy for breast cancer decreases plasma protein C and protein S. J Clin Oncol 6 (1988) 276-281
141. Kindler H.L., Friberg G., Singh D.A., et al. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 23 (2005) 8033-8040
142. Shah M.A., Ilson D., and Kelsen D.P. Thromboembolic events in gastric cancer: high incidence in patients receiving irinotecan- and bevacizumab-based therapy 10.1200/JCO. 2005. 81. 908. J Clin Oncol 23 (2005) 2574-2576
143. Kuenen B.C., Levi M., Meijers J.C., et al. Potential role of platelets in endothelial damage observed during treatment with cisplatin, gemcitabine, and the angiogenesis inhibitor SU5416. J Clin Oncol 21 (2003) 2192-2198
144. Ratain M.J., Eisen T., Stadler W.M., et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24 (2006) 2505-2512
145. Abou-Alfa G.K., Schwartz L., Ricci S., et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24 (2006) 4293-4300
146. Blom J.W., Doggen C.J., Osanto S., and Rosendaal F.R. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 293 (2005) 715-722
147. Pihusch R., Danzl G., Scholz M., et al. Impact of thrombophilic gene mutations on thrombosis risk in patients with gastrointestinal carcinoma. Cancer 94 (2002) 3120-3126
148. Haim N., Lanir N., Hoffman R., Haim A., Tsalik M., and Brenner B. Acquired activated protein C resistance is common in cancer patients and is associated with venous thromboembolism. Am J Med 110 (2001) 91-96
149. Ravin A.J., Edwards R.P., M. A.K., Kelley J.R., Christopherson W.A., and Roberts J.M. The factor V leiden mutation and the risk of venous thromboembolism in gynecologic oncology patients1. Obstet Gynecol 100 (2002) 1285-1289
150. Ramacciotti E., Wolosker N., Puech-Leao P., et al. Prevalence of factor V Leiden, FII G20210A, FXIII Val34Leu and MTHFR C677T polymorphisms in cancer patients with and without venous thrombosis. Thromb Res 109 (2003) 171-174
151. Eroglu A., Kurtman C., Ulu A., Cam R., and Akar N. Factor V Leiden and PT G20210A mutations in cancer patients with and without venous thrombosis. J Thromb Haemost 3 (2005) 1323-1324
152. Kennedy M., Andreescu A.C., Greenblatt M.S., et al. Factor V Leiden, prothrombin 20210A and the risk of venous thrombosis among cancer patients. Br J Haematol 128 (2005) 386-388